Epic Sciences

In the News


MedCity News: Cancer diagnostics firm that can enable personalized medicine raises $13M in Series B financing.

San Diego, MedCity News — San Diego-based biotech firm Epic Sciences announced Tuesday that the company has raised $13 million to pursue its molecular diagnostics technology that can better detect and monitor cancer as well as enable personalize cancer treatment.


Xconomist of the week: Peter Kuhn on detecting circulating tumor cells.

Xconomy — Worrying whether a solid tissue tumor might spread elsewhere in the body represents one of the biggest unknowns for many cancer patients, according to Peter Kuhn, an associate professor of cell biology at The Scripps Research Institute in San Diego.


Prostate Cancer Foundation: CTC technology detects presence of cancer and serves as a less invasive diagnostic tool.

Prostate Cancer Foundation — Through direct research funding and data sharing, the Prostate Cancer Foundation (PCF) funding has advanced the field of Circulating Tumor Cell (CTC) technology, which may soon deliver new gold standards for prostate cancer diagnostics and biomarkers.


Epic and Scripps publish five manuscripts in physical biology.

Click here for journal references.


Circulating tumor cells: The ultimate Assay?

San Diego, Clinical Oncology — Peter Kuhn, PhD, a professor of cell biology at Scripps Research Institute in La Jolla, Calif., has called circulating tumor cells "the messenger and the message of metastasis."